London, UK, October 2025: Closed Loop Medicine Ltd., a leader in personalized drug dosing, including using AI techniques, today announced that the United States Patent and Trademark Office has granted a patent relating to the personalized use of Cagrisema for obesity.

The grant further strengthens Closed Loop Medicine’s growing portfolio of intellectual property in GLP-1 and incretin therapies, which now includes four granted patents and more than 30 pending applications worldwide. The portfolio covers innovations in precision and personalized dosing, combination therapies, and the integration of patient-specific data with digital tools to improve treatment outcomes.

“GLP-1–based medicines are reshaping how we treat obesity and metabolic disease,” said Kate Woolland, CEO. “Our expanding IP estate ensures that Closed Loop Medicine is at the forefront of delivering personalized approaches that maximize efficacy and tolerability for patients, while creating strategic value in one of the fastest-growing areas of global pharma.”

The company, recently identified as one of the world’s top HealthTech Companies by Time, is actively looking to expand through partnerships and last month launched WeDosify, which enables clinicians to personalize GLP-1 titration at scale by delivering data-driven, adaptive dosing recommendations to improve GLP-1 adherence.

 

About Closed Loop Medicine

Closed Loop Medicine (CLM) is a health technology company delivering personalized treatment solutions through a proprietary platform underpinned by clinical evidence and data science.

By combining drug therapy with real-time patient data, the platform enables genuine personalization at scale for the first time, empowering clinicians and patients to make more informed decisions and drive better health outcomes. The Company partners with healthcare systems and pharmaceutical firms to deliver safer, more effective care across high-impact therapeutic areas.

For more information, visit www.closedloopmedicine.com, and follow Closed Loop Medicine on LinkedIn.